DOCSLIB.ORG

New Insights Into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Insights Into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair Published OnlineFirst April 2, 2014; DOI: 10.1158/1535-7163.MCT-13-0906-T Molecular Cancer Cancer Biology and Signal Transduction Therapeutics New Insights into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair Petar Jelinic and Douglas A. Levine Abstract In preclinical and clinical studies, olaparib and veliparib are the most represented PARP inhibitors (PARPi), which mainly target homologous DNA damage repair pathway-deficient cancer cells. Their off-target effects are not fully understood, especially with regard to cell cycle and homology-directed DNA damage repair. Our objective was to comparatively evaluate olaparib and veliparib in this context and correlate our findings with their therapeutic potential. We used a well-established direct repeat GFP (DR-GFP) reporter assay in U2OSDR-GFP and H1299DR-GFP cells and measured DNA damage repair activity upon drug treatment. Olaparib-treated U2OSDR-GFP cells showed a dramatic decrease in DNA damage repair versus veliparib irrespective of inhibitory potency. We demonstrate that this effect was a result of olaparib’s strong effect on the cell cycle. Unlike in veliparib-treated U2OSDR-GFP cells, in olaparib-treated cells S-phase decreased and G2-phase increased sharply, indicating a G2-phase arrest-like state and replicative stress. This was further confirmed by upregulation of p53 and p21 and accumulation of cyclin A. Lack of the same effect in p53-null H1299DR-GFP cells suggested that olaparib’s effect is p53 related, which was confirmed in p53-depleted U2OSDR-GFP and p53-null HCT116 cells. Importantly, we also demonstrate that olaparib, but not veliparib, induced a robust phosphorylation of Chk1, a crucial component of the replicative stress response pathway. Our data show olaparib and veliparib differ in their off-target effects; olaparib, unlike veliparib, mitigates DNA damage repair activity via G2 cell-cycle arrest-like effect in a p53-dependent manner. These off-target effects may add to PARPis’ anticancer properties. Mol Cancer Ther; 13(6); 1645–54. Ó2014 AACR. Introduction strand breaks (DSB), which are repaired predominantly PARP inhibitors (PARPi) target PARPs by suppres- by the homology-directed DNA damage repair (HDR) sing their enzymatic activity PARylation—the attach- pathway. If the HDR pathway is impaired, cells rely on ment of poly (ADP)-ribose polymers onto themselves more error-prone pathways, resulting in genomic insta- and other acceptor proteins (1, 2). PARP-1, the most bility and loss of viability (7, 8). PARP inhibition in abundant among all PARPs, is a stress-sensing protein HDR-compromised cells was the first demonstration of that acts mainly via the base excision repair (BER) the concept of synthetic lethality working in cancer pathway. One of the proposed mechanisms is that cells. This provided a strong rationale for the develop- PARP-1 binds to single-strand break (SSB) intermedi- ment of PARPis as a treatment for patients with cancer ates. After binding and self-PARylating, PARP-1 dis- with an impaired HDR pathway (9, 10). sociates from the SSB, which subsequently triggers the Olaparib and veliparib are the most extensively stud- downstream BER pathway to repair the lesion (3). It has ied PARPis in preclinical and clinical studies, showing been suggested that PARP inhibition impairs the BER greatest success in ovarian and breast cancers (11–14). pathway by trapping PARP-1 at the SSBs and blocking Although data from early clinical trials looking at PAR- further repair (4–6). When the replication fork encoun- Pis were promising, more recent results have failed to ters these SSBs, they are converted into DNA double- meet expectations, prompting a call for a better under- standing of these drugs’ mode of action (15). PARPis are þ nicotinamide (NAM) mimetics that compete with NAD for the NAM pocket within PARPs’ catalytic domain (16, Authors' Affiliation: Gynecology Service, Department of Surgery, Memo- rial Sloan Kettering Cancer Center, New York, New York 17). Although specifically developed as PARP-1 inhibi- tors, all PARPis exhibit a polypharmacology targeting Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/). other members of the PARP family (16, 18). Olaparib and veliparib fall within the same group of PARPs with the Corresponding Author: Douglas A. Levine, Gynecology Service, Depart- ment of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York similar polypharmacology (16). It is well documented Avenue, New York, NY 10065, Phone: 212-639-8125; Fax: 212-717- that olaparib and veliparib have similar inhibitory effects 3214; E-mail: [email protected] on PARP-1’s enzymatic activity (19). However, their off- doi: 10.1158/1535-7163.MCT-13-0906-T target effects, which may contribute to their differential Ó2014 American Association for Cancer Research. therapeutic properties, are not fully understood. It has www.aacrjournals.org 1645 Downloaded from mct.aacrjournals.org on September 25, 2021. © 2014 American Association for Cancer Research. Published OnlineFirst April 2, 2014; DOI: 10.1158/1535-7163.MCT-13-0906-T Jelinic and Levine been demonstrated that some PARPis cause cell-cycle serial PARPi dilutions, U2OSDR-GFP (1 Â 106) cells and abrogation, which has been recognized as an off-target H1299DR-GFP (0.5 Â 106) cells were transfected by effect (20, 21). Only a few PARPis share this character- electroporation using Nucleofector (Amaxa) with 2 or istic, suggesting that it is not related to their enzymatic 1 mgpCMV-I-SceI,respectively. Cells were then split activity-targeted inhibitory properties. Considering that into 2 wells of a 6-well plate. After 72 hours, cells were the HDR pathway is active predominately during the harvested and prepared for either HDR or PARP replicative phase of the cell cycle, the concept of synthetic activity assessment. For HDR activity assessment, cells lethality caused by PARP inhibition works only in HDR- were harvested with 250 mL trypsin. An equal amount impaired cells in which cell cycle is not arrested. There- of media was added to neutralize trypsin, and per- fore, it is essential to evaluate PARPis’ therapeutic prop- centages of GFP-positive cells were determined by erties in the context of the cell cycle and HDR, which thus flow cytometry (FACSCalibur; Becton Dickinson). For far has not been addressed. The important question PARP activity assessment, we used Trevigen’s Univer- remains whether or not olaparib and/or veliparib, the sal Colorimetric PARP assay (#4677-096-K) according 2 most common PARPis in clinical trials, have an impact to the manufacturer’s directions, with minor modifica- on the cell cycle that could compromise HDR activity and tions. Briefly, cells were washed 3 times in ice-cold PBS render these inhibitors less effective in the context of and lysed with PARP lysis buffer supplemented with synthetic lethality. 400 mmol/L NaCl, 1% Triton X-100, 0.4 mmol/L phe- To address this hypothesis, we took advantage of a nylmethylsulfonylfluoride, and protease inhibitor well-established direct repeat GFP (DR-GFP) reporter cocktail (P8340; Sigma-Aldrich). After 30 minutes of assay to comparatively evaluate HDR activity in cells incubation on ice, with occasional flicking, the lysates treated with olaparib or veliparib. We report a significant were centrifuged for 15 minutes at 4C at 10,000 Â g. differential effect between the 2 PARPis on cell cycle and The supernatant was transferred to a fresh tube, and HDR activity irrespective of their catalytic inhibitory protein concentration was measured using a Bradford potency. This work provides a new insight into these 2 assay (#500-0006; Bio-Rad). Fifty micrograms of pro- PARPis’ mode of action, which may help define selection tein lysate was mixed with PARP Cocktail into a criteria when evaluating patients for treatment with ola- histone-coated 96-well dish. After 60 minutes of room parib, veliparib, or other PARPis. temperature incubation, theplatewaswashed4times in PBS, 50 mL of Strep-HRP was added, and it was Materials and Methods incubated for 20 minutes at room temperature. The Cell culture and drug preparation plate was washed 4 times in PBS, and then 50 mLof U2OSDR-GFP human osteosarcoma cell line was cultured TACS-Sapphire was added. After 15 minutes of incu- in high glucose (4.5 g/L) Dulbecco’s Modified Eagle bation in the dark, the reaction was stopped by adding Medium (DMEM-HG) supplemented with 10% fetal calf 50 mL of 0.2M HCl. The plate was read by a microplate DR-GFP serum (FCS) and 2 mmol/L L-glutamine. H1299 reader (Synergy HT; BioTek) at 450 nm. human non–small cell lung carcinoma and HCT116 À À [wild-type (WT) and p53 / ] colorectal carcinoma cell Cell-cycle analysis lines were cultured in RPMI media supplemented with After incubation in specific conditions, cells were har- 10% FCS. U2OSDR-GFP and H1299DR-GFP cell lines were vested and counted to ensure equal numbers of cells were kindly donated by Dr. S. Powell (Department of Radiation processed (1 Â 106). Cells were then washed with ice-cold À À Oncology, MSKCC). HCT116 (WT and p53 / ) cell lines PBS, fixed in 80% ethanol at À20C for a minimum of 2 were kindly donated by Dr. G. Schwartz (Department of hours to overnight. Subsequently, cells were washed in Medicine, MSKCC). All cell lines were authenticated by ice-cold PBS and stained with propidium iodide DNA the short tandem repeat DNA profiling method (Genetica staining solution containing RNase A (200 mg/mL), Triton DNA Laboratories) using the DSMZ database (http:// X-100 (0.1%, v/v), and propidium iodide (50 mg/mL) in www.dsmz.de/). All cells tested negative for mycoplas- PBS. After 20 minutes of incubation at 37C, the samples ma. Olaparib (#S1060), veliparib (#S1004), and PJ34 were stored at 4C and processed by flow cytometer (#S7300) were obtained from Selleck Chemicals.
Load more

Recommended publications
  • Mitosis Vs. Meiosis
    Mitosis vs. Meiosis In order for organisms to continue growing and/or replace cells that are dead or beyond repair, cells must replicate, or make identical copies of themselves. In order to do this and maintain the proper number of chromosomes, the cells of eukaryotes must undergo mitosis to divide up their DNA. The dividing of the DNA ensures that both the “old” cell (parent cell) and the “new” cells (daughter cells) have the same genetic makeup and both will be diploid, or containing the same number of chromosomes as the parent cell. For reproduction of an organism to occur, the original parent cell will undergo Meiosis to create 4 new daughter cells with a slightly different genetic makeup in order to ensure genetic diversity when fertilization occurs. The four daughter cells will be haploid, or containing half the number of chromosomes as the parent cell. The difference between the two processes is that mitosis occurs in non-reproductive cells, or somatic cells, and meiosis occurs in the cells that participate in sexual reproduction, or germ cells. The Somatic Cell Cycle (Mitosis) The somatic cell cycle consists of 3 phases: interphase, m phase, and cytokinesis. 1. Interphase: Interphase is considered the non-dividing phase of the cell cycle. It is not a part of the actual process of mitosis, but it readies the cell for mitosis. It is made up of 3 sub-phases: • G1 Phase: In G1, the cell is growing. In most organisms, the majority of the cell’s life span is spent in G1. • S Phase: In each human somatic cell, there are 23 pairs of chromosomes; one chromosome comes from the mother and one comes from the father.
    [Show full text]
  • Targeting the WEE1 Kinase As a Molecular Targeted Therapy for Gastric Cancer
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 31 Research Paper Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer Hye-Young Kim1,2, Yunhee Cho1,3, HyeokGu Kang1,3, Ye-Seal Yim1,3, Seok-Jun Kim1,3, Jaewhan Song2, Kyung-Hee Chun1,3 1Department of Biochemistry & Molecular Biology, Yonsei University College of Medicine, Seodaemun-gu, Seoul 03722, Korea 2Department of Biochemistry, College of Life Science and Biotechnology, Seodaemun-gu, Seoul 03722, Korea 3Brain Korea 21 PlusProject for Medical Science, Yonsei University, Seodaemun-gu, Seoul 03722, Korea Correspondence to: Kyung-Hee Chun, email: [email protected] Keywords: WEE1, AZD1775 (MK-1775), 5-FU, Paclitaxel, gastric cancer Received: September 07, 2015 Accepted: May 28, 2016 Published: June 23, 2016 ABSTRACT Wee1 is a member of the Serine/Threonine protein kinase family and is a key regulator of cell cycle progression. It has been known that WEE1 is highly expressed and has oncogenic functions in various cancers, but it is not yet studied in gastric cancers. In this study, we investigated the oncogenic role and therapeutic potency of targeting WEE1 in gastric cancer. At first, higher expression levels of WEE1 with lower survival probability were determined in stage 4 gastric cancer patients or male patients with accompanied lymph node metastasis. To determine the function of WEE1 in gastric cancer cells, we determined that WEE1 ablation decreased the proliferation, migration, and invasion, while overexpression of WEE1 increased these effects in gastric cancer cells. We also validated the clinical application of WEE1 targeting by a small molecule, AZD1775 (MK-1775), which is a WEE1 specific inhibitor undergoing clinical trials.
    [Show full text]
  • The Cell Cycle & Mitosis
    The Cell Cycle & Mitosis Cell Growth The Cell Cycle is G1 phase ___________________________________ _______________________________ During the Cell Cycle, a cell ___________________________________ ___________________________________ Anaphase Cell Division ___________________________________ Mitosis M phase M ___________________________________ S phase replication DNA Interphase Interphase is ___________________________ ___________________________________ G2 phase Interphase is divided into three phases: ___, ___, & ___ G1 Phase S Phase G2 Phase The G1 phase is a period of The S phase replicates During the G2 phase, many of activity in which cells _______ ________________and the organelles and molecules ____________________ synthesizes _______ molecules. required for ____________ __________ Cells will When DNA replication is ___________________ _______________ and completed, _____________ When G2 is completed, the cell is synthesize new ___________ ____________________ ready to enter the ____________________ ____________________ ____________________ ____________________ ____________________ Mitosis are divided into four phases: _____________, ______________, _____________, & _____________ Below are cells in two different phases of the cell cycle, fill in the blanks using the word bank: Chromatin Nuclear Envelope Chromosome Sister Chromatids Nucleolus Spinder Fiber Centrosome Centrioles 5.._________ 1.__________ v 6..__________ 2.__________ 7.__________ 3.__________ 8..__________ 4.__________ v The Cell Cycle & Mitosis Microscope Lab:
    [Show full text]
  • The Cell Cycle Coloring Worksheet
    Name: Date: Period: The Cell Cycle Coloring Worksheet Label the diagram below with the following labels: Anaphase Interphase Mitosis Cell division (M Phase) Interphase Prophase Cytokinesis Interphase S-DNA replication G1 – cell grows Metaphase Telophase G2 – prepares for mitosis Then on the diagram, lightly color the G1 phase BLUE, the S phase YELLOW, the G2 phase RED, and the stages of mitosis ORANGE. Color the arrows indicating all of the interphases in GREEN. Color the part of the arrow indicating mitosis PURPLE and the part of the arrow indicating cytokinesis YELLOW. M-PHASE YELLOW: GREEN: CYTOKINESIS INTERPHASE PURPLE: TELOPHASE MITOSIS ANAPHASE ORANGE METAPHASE BLUE: G1: GROWS PROPHASE PURPLE MITOSIS RED:G2: PREPARES GREEN: FOR MITOSIS INTERPHASE YELLOW: S PHASE: DNA REPLICATION GREEN: INTERPHASE Use the diagram and your notes to answer the following questions. 1. What is a series of events that cells go through as they grow and divide? CELL CYCLE 2. What is the longest stage of the cell cycle called? INTERPHASE 3. During what stage does the G1, S, and G2 phases happen? INTERPHASE 4. During what phase of the cell cycle does mitosis and cytokinesis occur? M-PHASE 5. During what phase of the cell cycle does cell division occur? MITOSIS 6. During what phase of the cell cycle is DNA replicated? S-PHASE 7. During what phase of the cell cycle does the cell grow? G1,G2 8. During what phase of the cell cycle does the cell prepare for mitosis? G2 9. How many stages are there in mitosis? 4 10. Put the following stages of mitosis in order: anaphase, prophase, metaphase, and telophase.
    [Show full text]
  • Absence of a Measurable G2 Phase in Two Chinese Hamster Cell Lines (Cell Cycle/V79 Cells/Autoradiography) R
    Proc. Natl. Acad. Sci. USA Vol. 74, No. 4, pp. 1622-1625, April 1977 Cell Biology Absence of a measurable G2 phase in two Chinese hamster cell lines (cell cycle/V79 cells/autoradiography) R. MICHAEL LISKAY Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, Colorado 80309 Communicated by David M. Prescott, January 28, 1977 ABSTRACT Evidence is resented that demonstrates the been dipped in H20 and either air- or flame-dried. The slides absence of a measurable G2 prase in the cell cycles of two sub- were coated with NTB2 emulsion, dried, exposed for 7-28 days, lines of the Chinese hamster lung fibroblast V79. One of the sublines, in addition, lacks a detectable G1 phase, thereby pos- developed, and stained with crystal violet or Giemsa. The slides sessing a cell cycle comprised of simply two phases, DNA syn- were then scored for % labeled nuclei and % labeled meta- thesis (S) and mitosis (M). phases. An estimation of the length of the mitotic stages in V79-8 was The cell life cycle of most mammalian cells can be described obtained by examining living cells as they grew at 370 in flasks in terms of four phases (1): mitosis (M), a period between mitosis placed on the stage of an inverted phase contrast microscope. and the initiation of DNA replication (G1), DNA replication The first visible change in nuclear morphology (i.e., nuclear (S), and a period between the termination of DNA replication condensation as evidenced by a grainy appearance of the nu- and the beginning of prophase (G2).
    [Show full text]
  • Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy
    Author Manuscript Published OnlineFirst on March 27, 2020; DOI: 10.1158/1078-0432.CCR-19-3373 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy Linlin Yang1, Changxian Shen1, Cory Pettit1, Tianyun Li1, Andrew Hu1, Eric Miller1, Junran Zhang1, Steven H. Lin2, Terence M. Williams1, * 1The Ohio State University Medical Center, Arthur G. James Comprehensive Cancer Center and Richard J. Solove Research Institute, Columbus, Ohio. 2The University of Texas MD Anderson Cancer Center, Houston, Texas. *Corresponding Author: Terence M. Williams, Department of Radiation Oncology, The Ohio State University, 460 W. 12th Avenue, BRT/Room 492, Columbus, OH 43210-1280. Phone: (614) 293-3244. Fax: 614-293-4044. E-mail: [email protected] Running title: Targeting Wee1 for radiosensitization of esophageal cancer Key words: Wee1, AZD1775, G2 checkpoint, mitotic catastrophe, esophageal cancer Conflicts of Interest: The authors report no potential conflicts of interest. Financial Disclosure Statements: All authors have no competing financial interests to disclose. Funding Support: This work was supported by the following grants: The Ohio State University Comprehensive Cancer Center (OSU-CCC), National Institutes of Health (P30 CA016058 and R01 CA198128), and National Center for Advancing Translational Sciences (KL2TR001068). 1 Downloaded from clincancerres.aacrjournals.org on September 29, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on March 27, 2020; DOI: 10.1158/1078-0432.CCR-19-3373 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ABSTRACT Purpose: Esophageal cancer (ESCA) is a deadly malignancy with a 5-year survival rate of only 5-20%, which has remained unchanged for decades.
    [Show full text]
  • Role of Wild Type P53 in the G2 Phase: Regulation of the G-Irradiation- Induced Delay and DNA Repair
    Oncogene (1997) 15, 2597 ± 2607 1997 Stockton Press All rights reserved 0950 ± 9232/97 $12.00 Role of wild type p53 in the G2 phase: regulation of the g-irradiation- induced delay and DNA repair Dov Schwartz, Nava Almog, Amnon Peled, Naomi Gold®nger and Varda Rotter Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel 76100 Upregulation of the p53 protein was shown to induce cell al., 1995; Wells, 1996). We have recently found that cycle arrest at the G1/S border and in some cases at the both the loss of wild type p53, or overexpression of G2/M border. Furthermore, it was suggested that p53 is mutant p53 in myeloid cells, are associated with associated with the induction of the various DNA repair polyploidity (Peled et al., 1996). This supports the pathways. Previously, we demonstrated that cells co- conclusion that p53 may play a role at the spindle expressing endogenous wild type p53 protein, together checkpoint. with dominant negative mutant p53, exhibit deregulation p53 was shown to be involved in active cellular of apoptosis, G1 arrest and delay in G2 following g- repsonses that remove DNA damage, either by repair irradiation. In the present study, we investigated the role of the damaged DNA, or by an active killing of p53 protein in the DNA damage response at the G2 (apoptosis) of cells possessing extensive, unrepairable phase. Using p53-null, wild type p53 and mutant p53- DNA damage (reviewed in Enoch and Norbury, 1995). producer cell lines, we found that the two C-terminally p53-dependent apoptosis is triggered by various stress spliced p53 forms could prevent g-irradiation induced conditions, resulting in a clastrogenic eect on the mutagenesis prior to mitosis, at the G2/M checkpoint.
    [Show full text]
  • Cyclin-Dependent Kinase 6 Is the Principal Target of P27ikipl Regulation of the G1-Phase Traverse in 1,25-Dihydroxyvitamin D3-Treated HL6O Cells'
    [CANCER RESEARCH57. 2851—2855.July15. 19971 Advances in Brief Cyclin-dependent Kinase 6 Is the Principal Target of p27IKipl Regulation of the G1-phase Traverse in 1,25-Dihydroxyvitamin D3-treated HL6O Cells' Qing Mei Wang, Xun Luo, and George P. Studzinski2 Department of Pathology and Laboratory Medicine, University ofMedicine and Dentistry ofNew Jersey-New Jersey Medical School, Newark, New Jersey 07103 Abstract specific increase in Cdk6-associated p27/Kipl protein in l,25D3- treated wild-type HL6O (HL6O-G) cells but not in a 1,25D3-resistant Control of cell proliferation remains of intense interest in cancer re subline of HL6O (4OAF) cells. This provides a mechanism for 1,25D3- search. In the 1,25-dihydroxyvitamin D3 HL6O cell system, G1 arrest has mediated G1 arrest in wild-type HL6O cells. been shown to be mediated by elevated levels of p27/Kipi protein. We show here that the main target of the elevated p27IKipl in this system is Materials and Methods cyclin-dependent kinase (Cdk) 6. The activity of Cdk2 is also down regulated, and this is associated with altered and reduced levels of cyclin Cell Culture. HL6O-Gcells,a subcloneof HL6Opromyelocyticleukemia E in the kinase complex. Paradoxically, the kinase activity of Cdk4 is cells, were maintained in RPMI 1640 supplemented with I% glutamine and elevated, in spite ofan almost complete G1 block. These data show that the 10% complement-inactivated bovine calf serum. The 1,25D3-resistant HL6O functions of Cdk4 and Cdk6 are not redundant and that Cdk6 and Cdk2 subline (4OAF) was derived as described (4).
    [Show full text]
  • Activity and Expression Pattern of Cyclin-Dependent Kinase 5 in the Embryonic Mouse Nervous System
    Development 119, 1029-1040 (1993) 1029 Printed in Great Britain © The Company of Biologists Limited 1993 Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system Li-Huei Tsai1,*, Takao Takahashi2, Verne S. Caviness Jr2 and Ed Harlow1 1Massachusetts General Hospital Cancer Center, Building 149, 13th Street, Charlestown, MA 02129, USA 2Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA *Author for correspondence SUMMARY Cyclin-dependent kinase 5 (cdk5) was originally isolated ing and fell to barely detectable levels at E17 at the end on the basis of its close primary sequence homology to of the cytogenetic period. Immunohistochemical studies the human cdc2 serine/threonine kinase, the prototype showed that cdk5 is expressed in postmitotic neurons but of the cyclin-dependent kinases. While kinase activities not in glial cells or mitotically active cells. Expression of of both cdc2 and cdk2 are detected in proliferating cells cdk5 was concentrated in fasciculated axons of postmi- and are essential for cells to progress through the key totic neurons. In contrast to other cell division cycle transition points of the cell cycle, cdk5 kinase activity has kinases to which it is closely related, cdk5 appears not to been observed only in lysates of adult brain. In this be expressed in dividing cells in the developing brain. study, we compared the activity and expression of cdk5 These observations suggest that cdk5 may have a role in with that of cdc2 and cdk2 in the embryonic mouse neuronal differentiation but not in the cell division cycle forebrain.
    [Show full text]
  • Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells
    G C A T T A C G G C A T genes Article Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells Michèle J. Hoffmann * , Sarah Meneceur †, Katrin Hommel †, Wolfgang A. Schulz and Günter Niegisch Department of Urology, Medical Faculty, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany; [email protected] (S.M.); [email protected] (K.H.); [email protected] (W.A.S.); [email protected] (G.N.) * Correspondence: [email protected]; Tel.: +49-21-1811-5847 † Contributed equally. Abstract: Since genes encoding epigenetic regulators are often mutated or deregulated in urothelial carcinoma (UC), they represent promising therapeutic targets. Specifically, inhibition of Class-I histone deacetylase (HDAC) isoenzymes induces cell death in UC cell lines (UCC) and, in contrast to other cancer types, cell cycle arrest in G2/M. Here, we investigated whether mutations in cell cycle genes contribute to G2/M rather than G1 arrest, identified the precise point of arrest and clarified the function of individual HDAC Class-I isoenzymes. Database analyses of UC tissues and cell lines revealed mutations in G1/S, but not G2/M checkpoint regulators. Using class I-specific HDAC inhibitors (HDACi) with different isoenzyme specificity (Romidepsin, Entinostat, RGFP966), cell cycle arrest was shown to occur at the G2/M transition and to depend on inhibition of HDAC1/2 Citation: Hoffmann, M.J.; rather than HDAC3. Since HDAC1/2 inhibition caused cell-type-specific downregulation of genes Meneceur, S.; Hommel, K.; Schulz, encoding G2/M regulators, the WEE1 inhibitor MK-1775 could not overcome G2/M checkpoint W.A.; Niegisch, G.
    [Show full text]
  • Absence of Wee1 Ensures the Meiotic Cell Cycle in Xenopus Oocytes
    Downloaded from genesdev.cshlp.org on September 29, 2021 - Published by Cold Spring Harbor Laboratory Press Absence of Wee1 ensures the meiotic cell cycle in Xenopus oocytes Nobushige Nakajo,1 Satoshi Yoshitome,1 Jun Iwashita,1,2 Maki Iida, Katsuhiro Uto, Shuichi Ueno, Kengo Okamoto, and Noriyuki Sagata3 Department of Biology, Graduate School of Science, Kyushu University, Fukuoka 812-8581, Japan Meiotic cells undergo two successive divisions without an intervening S phase. However, the mechanism of S-phase omission between the two meiotic divisions is largely unknown. Here we show that Wee1, a universal mitotic inhibitor, is absent in immature (but not mature) Xenopus oocytes, being down-regulated specifically during oogenesis; this down-regulation is most likely due to a translational repression. Even the modest ectopic expression of Wee1 in immature (meiosis I) oocytes can induce interphase nucleus reformation and DNA replication just after meiosis I. Thus, the presence of Wee1 during meiosis I converts the meiotic cell cycle into a mitotic-like cell cycle having S phase. In contrast, Myt1, a Wee1-related kinase, is present and directly involved in G2 arrest of immature oocytes, but its ectopic expression has little effect on the meiotic cell cycle. These results strongly indicate that the absence of Wee1 in meiosis I ensures the meiotic cell cycle in Xenopus oocytes. Based on these results and the data published previously in other organisms, we suggest that absence of Wee1 may be a well-conserved mechanism for omitting interphase or S phase between the two meiotic divisions. [Key Words: Cell cycle; meiosis; Mos; S phase; Wee1; Xenopus oocyte] Received November 9, 1999; revised version accepted December 14, 1999.
    [Show full text]
  • Phosphatases Reverse P53-Mediated Cell Cycle Checkpoints
    COMMENTARY Phosphatases reverse p53-mediated cell cycle checkpoints Lawrence A. Donehower1 for the damage or dysfunction to be repaired Departments of Molecular Virology and Microbiology, Molecular, and Cellular Biology, Pediatrics without being transmitted to progeny cells. and the Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030 Thus, p53 has been called the “guardian of the genome” (3).Giventheimportanceof p53 as a cellular failsafe mechanism, it is The Cancer Genome Atlas and other large- In the normal cell, the p53 protein func- not surprising that its inactivation is a highly scale cancer genome sequencing projects tions as a stress integrator that becomes selected event in cancer progression. have identified an impressive number of activated in response to myriad dysfunctional Activated p53 can halt cell division in both states (e.g., damaged DNA, aberrant onco- significantly mutated genes that are likely the G1 and G2 phases of the cell division genic signaling, and hypoxia). Once activated, drivers of cancer progression (1). These stud- cycle. G1 is the preparation phase of the cell p53 can initiate stress response programs to ies have definitively confirmed that the gene before replication of its DNA and G2 pre- eliminate the dysfunctional state, such as encoding the p53 tumor suppressor is the pares the cell for mitosis. Arrest and repair of repair of DNA damage. If the stressed cell most frequently mutated gene in human can- cells before DNA replication or mitosis are is dividing, p53 can enact any one of several cers. A major component of the p53 antican- likely to prevent damage-induced mutational antiproliferative programs.
    [Show full text]